nUro, Inc. Receives Investment From >60 Accredited Investors

DALLAS - March 13, 2015 - PRLog -- nUro, Inc. announced today that it has closed an investment round with a group of investors from the US and Europe.  This investment will enable the Company to comply with the minimum accredited investors required to be publicly traded on the OTC-QB.

nUro, Inc. is a medical device manufacturer developing technologies that interface with the nervous system to provide targeted therapy for the relief of chronic diseases.  The Company’s SynapseTM platform received the CE Mark for the treatment of certain movement disorders.  nUro, Inc. is continuing to develop the platform and expand its field of use. The Company has a number of ongoing preclinical and clinical studies supporting development of the SynapseTM platform for OAB, atrial fibrillation, and other indications treatable with neuromodulation.

The Company expects to file a Form 10 Registration Statement with the SEC later this year in order to begin the process of becoming a full reporting public company during 2015.  The Company will be seeking its initial listing on the OTC Markets:QB Exchange where it will be required to meet certain eligibility standards aimed at improving the public information available to investors.  Once listed in the US, the Company will seek listing on one or more EU Exchanges.

“With nearly 2 years of runway in hand to support programs in overactive bladder, atrial fibrillation, and movement disorders, we will be able to achieve our clinical inflection points without needing to raise funds via an initial public offering.  We believe that by becoming a reporting company we will increase transparency and ultimately value in the stock for future investors,” said CEO Will Rosellini.  The Company must file annual reports on Form 10-K, quarterly reports on Form 10-Q, and periodic reports on Form 8-K. In addition, the Company will be subject to ownership and reporting requirements of Sections 13 and 16 of the Exchange Act.

About nUro, Inc. - nUro, Inc. arose from viable clinical programs developed internally and acquired from Medtronic. These programs were initiated at Rosellini Scientific via support from the National Institutes of Health (NIH) SBIR program.  The formation of nUro, Inc. was finalized with the acquisition of Synaptix, a vertically integrated medical device manufacturing company with a CE Marked deep brain stimulator. This 16-channel recording and stimulation platform (SynapseTM) has been deployed in clinical studies for the treatment of movement disorders. In addition, the Company developed a wireless version of the device for use in the peripheral nervous system, most notably for the treatment of urological disorders. nUro, Inc. has now produced and tested its device conforming to Good Manufacturing Practice (GMP) in its class 10,000 clean-room.

For more information on Nuro, please visit our website at http://www.nurocorp.com

Photo:
https://www.prlog.org/12435210/1